Mostrar el registro sencillo del ítem

dc.contributorUniversitat Ramon Llull. Facultat de Ciències de la Salut Blanquerna
dc.contributor.authorAmorós-Reboredo, Patrícia
dc.contributor.authorSoy Muner, Dolors
dc.contributor.authorHernández Hernández, Marta
dc.contributor.authorLens, Sabela
dc.contributor.authorMestres Miralles, Concepción
dc.date.accessioned2021-02-12T08:25:23Z
dc.date.accessioned2023-07-12T12:05:18Z
dc.date.available2021-02-12T08:25:23Z
dc.date.available2023-07-12T12:05:18Z
dc.date.created2020-03
dc.date.issued2020-05
dc.identifier.urihttp://hdl.handle.net/20.500.14342/743
dc.description.abstractAim: Older patients with chronic hepatitis C infection starting direct-acting antivirals (DAAs) are frequently prescribed multiple medications that may be categorized as inappropriate. Anticholinergic burden has been shown to be a predictor of adverse health and functional outcomes. Different scales are available to calculate anticholinergic burden. The aim of this study was to determine the prevalence of anticholinergic medication among older patients treated with DAAs and the risk factors associated using the Anticholinergic Cognitive Burden (ACB) scale, the Anticholinergic Risk Scale (ARS) and the Anticholinergic Drug Scale (ADS) and analyze the resulting safety consequences. Methods: Observational, retrospective cohort study of consecutive patients ≥65 years old receiving DAAs and taking concomitant medication. This study was conducted in accordance with the Strengthening the Reporting of observational studies in Epidemiology Statement. Results: 236 patients were included. The average age was 71.7 years, 73.3% cirrhotic, and 47% patients took ≥5 medicines. According to the ACB, ARS and ADS scales, 35.2% (n = 83), 10.6% (n = 25) and 34.3% (n = 81) of the patients were treated with anticholinergic medication. Two hundred-and-six (86%) patients presented any adverse events (AEs) during therapy. ARS scale showed a significant relationship between presence of anticholinergic medication and AEs. A large number of patients suffered anticholinergic events, with more events per patient in patients taking anticholinergic drugs. Conclusions: Older hepatitis C chronic patients are exposed to potentially inappropriate polypharmacy and anticholinergic risk, according to the ACB, ARS and ADS scales. The three scales showed different results. Only the ARS scale was associated with AEs, but the rate of anticholinergic effects per patient was significantly higher in patients with anticholinergic drugs, regardless of the scale used. Consider quality of pharmacotherapy when starting DAA with a multidisciplinary approach could improve health outcomes.eng
dc.format.extent14 p.cat
dc.language.isoengcat
dc.publisherMDPIcat
dc.relation.ispartofInternational Journal of Environmental Research and Public Health, 2020, vol. 17, núm. 11cat
dc.rightsAttribution 4.0 International
dc.rights© L'autor/a
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceRECERCAT (Dipòsit de la Recerca de Catalunya)
dc.subject.otherHepatitis C--Tractamentcat
dc.subject.otherMedicaments--Administraciócat
dc.subject.otherPersones grans--Malalties--Tractamentcat
dc.titleAnticholinergic burden and safety outcomes in older patients with chronic hepatitis C: A retrospective cohort studycat
dc.typeinfo:eu-repo/semantics/articlecat
dc.typeinfo:eu-repo/semantics/publishedVersioncat
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapcat
dc.subject.udc615
dc.subject.udc616.9
dc.identifier.doihttps://doi.org/10.3390/ijerph17113776cat


Ficheros en el ítem

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by/4.0/
Compartir en TwitterCompartir en LinkedinCompartir en FacebookCompartir en TelegramCompartir en WhatsappImprimir